These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
52 related articles for article (PubMed ID: 7716673)
1. [Characteristics of patients with low grade malignant lymphoma and long survival]. Martínez-Francés A; Lopez-Guillermo A; Esteve J; Bosch F; Terol MJ; Montserrat E; Rozman C Sangre (Barc); 1995 Feb; 40(1):53-7. PubMed ID: 7716673 [TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074 [TBL] [Abstract][Full Text] [Related]
3. [Non-Hodgkin's lymphomas. II. Analysis of the prognostic factors in a series of 307 patients]. García Zueco JC; Delgado MP; Giraldo MP; Perella M; Rubio-Félix D; Giralt M Sangre (Barc); 1992 Oct; 37(5):337-44. PubMed ID: 1293772 [TBL] [Abstract][Full Text] [Related]
4. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. van Besien KW; Mehra RC; Giralt SA; Kantarjian HM; Pugh WC; Khouri IF; Moon Y; Williams P; Andersson BS; Przepiorka D; McCarthy PL; Gajewski JL; Deisseroth AB; Cabanillas FF; Champlin R Am J Med; 1996 Mar; 100(3):299-307. PubMed ID: 8629675 [TBL] [Abstract][Full Text] [Related]
5. [Post-therapeutic evolution and prognostic factors of intestinal lymphomas, Retrospective analysis of 42 cases]. Sánchez-Fayos MP; Hernández Guío C; Rivas MC; Outeiriño J; González-Campos C; Lobo F Sangre (Barc); 1993 Dec; 38(6):455-62. PubMed ID: 8171381 [TBL] [Abstract][Full Text] [Related]
6. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response. Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350 [TBL] [Abstract][Full Text] [Related]
7. Primary non-Hodgkin lymphoma of the breast: The Mayo Clinic Experience. Wong WW; Schild SE; Halyard MY; Schomberg PJ J Surg Oncol; 2002 May; 80(1):19-25; discussion 26. PubMed ID: 11967901 [TBL] [Abstract][Full Text] [Related]
8. Treatment results of tonsillar lymphoma: a 10-year experience. Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316 [TBL] [Abstract][Full Text] [Related]
9. Low-grade non-Hodgkin's lymphoma in northern Norway: treatment, outcome, and prognostic factors. Bremnes RM; Vik A; Helbekkmo N Anticancer Res; 1998; 18(3B):1921-9. PubMed ID: 9677445 [TBL] [Abstract][Full Text] [Related]
10. [Long-term survival in chronic myeloid leukemia: frequency and fundamental characteristics in a series of 100 patients]. Cervantes F; Bosch F; Terol MJ; Pereira A; Rozman C Sangre (Barc); 1993 Apr; 38(2):93-6. PubMed ID: 8516734 [TBL] [Abstract][Full Text] [Related]
11. [Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice]. Farzad M; De Luca MC; Rubino G; Pirtoli L; Pepi F; Sebaste L; Ponticelli P; Atzeni G; Maranzano E; Silvano G Radiol Med; 2001; 102(1-2):72-7. PubMed ID: 11677442 [TBL] [Abstract][Full Text] [Related]
12. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage]. Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383 [TBL] [Abstract][Full Text] [Related]
13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival. van Besien K; Rodriguez A; Tomany S; Younes A; Donato M; Sarris A; Giralt S; Mehra R; Andersson B; Gajewski J; Champlin R; Cabanillas F Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669 [TBL] [Abstract][Full Text] [Related]
15. [Prognostic factors in low-grade lymphoma]. Gandarillas MA; Conde E; Mazorra F; Cuadrado MA; Baro J; Garijo J; Recio M; Richard C; Iriondo A; Zubizarreta A Sangre (Barc); 1998 Jun; 43(3):185-90. PubMed ID: 9741223 [TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737 [TBL] [Abstract][Full Text] [Related]
18. [Aplastic anemia--clinical characteristics and survival analysis]. Milosević R; Antonijević N; Janković G; Babić D; Colović M Srp Arh Celok Lek; 1998; 126(7-8):234-8. PubMed ID: 9863388 [TBL] [Abstract][Full Text] [Related]
19. Primary non-Hodgkin's lymphoma of the bone: treatment and analysis of prognostic factors for Stage I and Stage II. Barbieri E; Cammelli S; Mauro F; Perini F; Cazzola A; Neri S; Bunkheila F; Ferrari S; Brandoli V; Zinzani P; Mercuri M; Bacci G Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):760-4. PubMed ID: 15183479 [TBL] [Abstract][Full Text] [Related]
20. To what extent can indolent lymphoma be considered? Results of a long term follow-up study from a single center. Zinzani PL; Magagnoli M; Gherlinzoni F; Bendandi M; Albertini P; Merla E; Tura S Haematologica; 1998 Jun; 83(6):502-7. PubMed ID: 9676022 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]